Analysts are intrested in these 5 stocks: ( ($VRT) ), ( ($AFRM) ), ( ($SRPT) ), ( ($MU) ) and ( ($PEP) ). Here is a breakdown of their recent ...

On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to ...

The firm plans to seek accelerated approval from the FDA next year, while it launches a Phase III trial to support other regulatory applications.

Wedbush upgrades Sarepta Therapeutics, citing overdone selloff and potential upside as FDA could re-approval Elevidys for non ...

This article has been revised and clarified. Pasadena-based biopharma company Arrowhead Pharmaceuticals Inc. had a ...

Bristol Myers Squibb said it will enroll more patients in a key Phase 3 trial studying its drug Cobenfy in psychosis associated with Alzheimer’s disease, after the company found “irregularities due to ...

For the scientific enterprise, 2025 was marked by setbacks and challenges. But scientists are no strangers to adversity—the ability to overcome obstacles is built into our training. In turn, research ...

Capricor Therapeutics’ stock has soared by more than 370% after a pivotal trial of its Duchenne muscular dystrophy (DMD) cell ...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

A top Food and Drug Administration (FDA) official called for introspection, humility and transformation at the agency in an ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Acute liver injury has been associated with the death of two non-ambulatory DMD patients treated with Elevidys.